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Summary
T cell activation through the T cell receptor (TCR) is
subsequently modified by secondary signals that are
either stimulatory or inhibitory. We show that CEA-
CAM1 adhesion molecule isoforms containing a long
cytoplasmic domain inhibitedmultiple T cell functions
as a consequence of TCR ligation. Overexpression of
CEACAM1 resulted in decreased proliferation, alloge-
neic reactivity, and cytokine production in vitro and
delayed type hypersensitivity and inflammatory bowel
disease inmousemodels in vivo. Conditioned deletion
of CEACAM1 in T cells caused increased TCR-CD3
complex signaling. This T cell regulation was de-
pendent upon the presence of immunoreceptor tyro-
sine-based inhibitionmotifs (ITIM) within the cytoplas-
mic domain of CEACAM1 and the Src homology 2
domain-containing protein tyrosine-phosphatase 1
(SHP1) in the T cell. Thus, CEACAM1 overexpression
or deletion in T cells resulted in T cell inhibition or
activation, respectively, revealing a role for CEACAM1
as a class of inhibitory receptors potentially amenable
to therapeutic manipulation.
*Correspondence: rblumberg@partners.org
7 Present address: Department of Gastroenterology and Hepatol-
ogy, Graduate School of Medicine, Tokyo Medical and Dental
University, Tokyo 113-8519, Japan.Introduction
The activation of a T cell through the antigen-specific
T cell receptor (TCR)-CD3 complex by a major histo-
compatibility complex (MHC)-peptide complex is de-
pendent upon, and modified by, secondary signals that
are either stimulatory or inhibitory (Greenfield et al.,
1998). The major costimulatory and coinhibitory signals
for the majority of naive T cells are those delivered by
either CD28 or cytotoxic lymphocyte antigen (CTLA)-4,
respectively (Walunas et al., 1996). However, it has
been increasingly recognized that other CD28-related
secondary regulatory molecules exist that likely serve
similar functions (Ling et al., 2000). Non-CD28-related
molecules may have analogous positive and negative
regulation of T cells, but their in vivo importance remains
to be determined. One such candidate molecule is car-
cinoembryonic antigen (CEA)-related cell adhesion
molecule 1 (CEACAM1).
CEACAM1 is a type I-transmembrane glycoprotein
that is a member of the CEA superfamily and was origi-
nally identified in epithelial cells (Gray-Owen and Blum-
berg, 2006). The human CEA superfamily consists of
19 genes and pseudogenes on chromosome 19q13.3,
which encode proteins that are linked to the membrane
either by a glycophosphatidylinositol anchor, as is the
case for CEA (CEACAM5), or by a transmembrane re-
gion, as is the case for CEACAM1 (Obrink, 1997; Thomp-
son et al., 1991). CEACAM1 is the only superfamily mem-
ber expressed in rodents and humans, suggesting that it
may be the original CEACAM gene family member
(Beauchemin et al., 1999). Mouse and human CEACAM1
transcripts undergo extensive alternative splicing that
generates 11 splice products in humans and 4 splice
products in mice. These isoforms are named for the
number of extracellular domains and the type of cyto-
plasmic (cyt) domain expressed (Beauchemin et al.,
1999). Each splice variant of CEACAM1 consists of
a membrane-distal IgV-like N-region, followed by vari-
able numbers of alternating IgC1 and IgC2 set regions,
a common transmembrane domain, and either a long
(-L, 73 aa) or short (-S, 10 aa) cyt domain (Beauchemin
et al., 1999). The L domain of CEACAM1 contains im-
mune receptor tyrosine-based inhibitory motifs (ITIM)
and has been linked to inhibitory signaling in epithelial
cells (Daeron and Vivier, 1999; Isakov, 1997). The pro-
posed inhibitory function of CEACAM1 in epithelial cells
is triggered by the phosphorylation of ITIM tyrosine res-
idues by Src-related kinases, resulting in recruitment of
the Src homology 2 (SH2) domain-containing protein-ty-
rosine phosphatases (SHP)-1 and -2 (Beauchemin et al.,
1997; Huber et al., 1999). Mice exhibit two allelic forms (a
and b) of CEACAM1 because of differences in the N-do-
main with most mouse strains, including C57BL/6J (B6),
expressing the CEACAM1a allele (Beauchemin et al.,
1999).
CEACAM1 is expressed by a variety of epithelial (Watt
et al., 1995), endothelial (Muenzner et al., 2000), and he-
matopoietic cell types including granulocytes (Watt
et al., 1991), monocytes, dendritic cells, natural killer
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770cells (Moller et al., 1996), and B lymphocytes (Khan
et al., 1993). We and others have recently observed
that CEACAM1, but not other CEACAM-related pro-
teins, is also expressed on the surface of human and
mouse CD4+ or CD8+ T cells immediately after activa-
tion through the TCR-CD3 complex ex vivo (Kammerer
et al., 1998; Moller et al., 1996; Morales et al., 1999; Na-
kajima et al., 2002). Although specific monoclonal anti-
bodies (mAb) do not exist to distinguish the various pro-
teins generated by alternate splicing, RNA analysis has
shown that human T cells express transcripts for CEA-
CAM1-4L, -4S, -3L, and -3S isoforms (Donda et al.,
2000; Singer et al., 2002) and mouse T cells express
CEACAM1-4L, -4S, -2L, and -2S isoforms (Beauchemin
et al., 1999; Tan et al., 2002). Semiquantitative analysis
in mouse and human T cells suggest that CEACAM1-L
isoforms predominate over CEACAM1-S isoforms
(Singer et al., 2002).
CEACAM1 exhibits homophilic ligation of the N-do-
main with the N-domains of another CEACAM1 mole-
cule or a CEACAM-related molecule, mainly CEACAM5
(CEA), CEACAM6, or CEACAM8 (Oikawa et al., 1992;
Watt et al., 2001). Heterophilic ligands also exist for
CEACAM1 and include E-selectin (CD62E) through ex-
pression of Lex or sLex on CEACAM1 expressed on
granulocytes (Stocks et al., 1996), galectin-3 (Feuk-La-
gerstedt et al., 1999), bacterial products (Boulton and
Gray-Owen, 2002), or viral proteins (Gagneten et al.,
1995). Several independent in vitro studies have shown
that this heterophilic ligation of CEACAM1 on T cells
with bacterial products of Neisseriae gonorrhea (Boul-
ton and Gray-Owen, 2002), the spike glycoprotein of
mouse hepatitis virus (Gagneten et al., 1995), or CEA-
CAM1-specific mAbs can inhibit different T cell func-
tions, consistent with the ability of the CEACAM1-L do-
main to associate with SHP1 (Boulton and Gray-Owen,
2002; Chen and Shively, 2004; Markel et al., 2002; Mo-
rales et al., 1999). These studies suggest that CEA-
CAM1-L isoforms may be inhibitory to T cells. Consis-
tent with this, we have observed that heterophilic
(mAb) or homophilic (CEACAM1-Fc fusion protein) liga-
tion of mouse CEACAM1 in vivo results in protection
from hapten-mediated colitis (Iijima et al., 2004). How-
ever, because mouse T cells express multiple different
CEACAM1 transcripts and because multiple different
cell types other than T cells express CEACAM1 in
vivo, the inhibition observed in these colitis models
could also have resulted from inhibition of CEACAM1-
activating functions on T cells or blockade of CEA-
CAM1 functions on non-T cells. Therefore, assignment
of a coinhibitory function to CEACAM1 remains un-
proven.
We have, therefore, generated model systems to
study the function of specific isoforms of CEACAM1
on T cells in vivo. Specifically, we established a retroviral
transfection system of primary T cells with the mouse
CEACAM1-2L splice variant together with conditional
deletion of SHP1 specifically in T cells and a transgenic
mouse that directs specific overexpression of the CEA-
CAM-4L isoform in T cells. The studies with these
models show multiple different CEACAM1 isoforms
that contain a long cyt domain possess the general
property of inhibiting T cell function in a pathway that
depends on the ITIM domains and SHP1.Results
Definition of CEACAM1-4L and -2L Function in
Primary T Cells
Because the CEACAM1-L isoforms are predicted to be
inhibitory and dominantly expressed in mouse and hu-
man T cells (Singer et al., 2002), we sought to determine
their function in primary mouse T cells. The Ceacam1a-
4L or -2L cDNA, cloned into GFP-RV (see Figure S1,
top, in the Supplemental Data available online; GFP-4L
or 2L, respectively), were packaged into retroviruses
and transduced into primary CD4+ splenocytes (SPL)
from B6 WT mice or NIH3T3 cells (Figure 1A). The effi-
ciency of GFP-4L and GFP-2L infection into NIH3T3
was greater than 90%, similar to the efficiency of infec-
tion by GFP-RV alone (VA, Figure 1A, top). Transfection
of CEACAM1-2L and -4L into primary T cells was con-
firmed by flow cytometry (Figure 1A, bottom) and immu-
nofluorescence (Figure 1B). However, the infection effi-
ciency of GFP-4L into primary T cells was lower than
that observed with GFP-2L (2L) or VA (Figure 1A, bot-
tom). Consistent with this, the ability of the GFP-4L-
transduced T cells to propagate was substantially lower
than that of the GFP-2L-infected T cells, which was
similar to the VA-transfected cells (data not shown).
After transfection of CD4+ T cells, GFP+ cells were
sorted and IL-2 production determined after stimulation
with anti-CD3 and anti-CD28 (Figure 1C) or PMA and
ionomycin (Figure 1D and Figure S1, middle). IL-2 pro-
duction from the CEACAM1-2L-transfected T cells was
suppressed in comparison to the VA transfectant after
anti-CD3-CD28 stimulation with less suppression ob-
served after PMA and ionomycin stimulation. The de-
creased IL-2 production by CEACAM1-2L was not due
to induction of apoptosis (Figure 1E). The CEACAM1-
4L isoform was profoundly inhibitory after anti-CD3
and anti-CD28 stimulation with persistent, but less, in-
hibition observed after PMA and ionomycin stimula-
tion. This suggests that CEACAM1-mediated inhibition
mainly affects signals that are proximal to ligation of
the TCR-CD3 complex.
Since overexpression of the CEACAM1-2L and -4L
splice variants in primary mouse CD4+ T cells caused
substantial inhibition of T cell function, it would be pre-
dicted that deletion of CEACAM1 would result in T cell
hyperresponsiveness to TCR-CD3 complex signaling.
We therefore created a T cell-specific Ceacam1 null
mouse and examined the response of T cells to anti-
CD3 and -CD28 stimulation. Ceacam1flox/flox mice con-
taining lox-P sites flanking exons 7–9 that encode the
cyt tail of CEACAM1 (see Experimental Procedures
and Figure S2) were crossed with mice expressing Cre
recombinase under the control of the proximal Lck
promoter, which is active in T cells within the thymus
and periphery. Ceacam1flox/flox mice expressed lower
amounts of CEACAM1 on B cells and hepatocytes
(Figure S2), consistent with the fact that insertion of
the neo cassette in intron 6 caused a slight decrease in
CEACAM1 protein expression prior toCre-mediated de-
letion, so Ceacam1flox/flox mice were used as controls.
Purified CD4+ T cells from the spleens ofCeacam1flox/flox
X Lck-Cre mice exhibited extinction of CEACAM1
protein expression as defined by immunoblotting with
the CC1 mAb in comparison to Ceacam1flox/flox mice
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771Figure 1. CEACAM1a-4L and -2L Transduction into Mouse CD4+ T Cells
(A) Retroviral infections. NIH3T3 cells (top) or primary CD4+ T cells (bottom) were infected with GFP-RV vector alone (VA), GFP-4L (4L), or GFP-2L
(2L). 36 hr after infection, cells were stained with CC1 and anti-mouse IgG1-PE and analyzed by flow cytometry.
(B) GFP and CEACAM1 expression of CD4+ T cell transfectants with GFP-RV (VA) and GFP-2L (2L). Cells were stained with CC1 and Alexa568-
conjugated anti-mouse IgG.
(C) IL-2 production by CD4+ GFP-RV infectants. Retrovirally infected cells were stained with anti-CD4 CyChrome, and CD4+GFP+ cells were
sorted by FACS and stimulated with anti-CD3 and anti-CD28. IL-2 production was determined by ELISA in triplicate after 48 hr of stimulation.
Bars indicate SEM. *p < 0.01; **p < 0.05.
(D) IL-2 production by CD4+ GFP-RV infectants after stimulation with phorbol ester (PMA) and ionomycin. Bars indicate SEM. *p < 0.05.
(E) Analysis of apoptosis after CEACAM1-2L transfection. CD4+ T cells were infected with either GFP-RV vector alone (VA) or GFP-2L (2L), and
sorted GFP+ cells were subjected to 7-AAD and Annexin-V staining. Numbers in quadrants indicate percent of cells.
(F) Proliferation of CEACAM1-deficient T cells. CD4+ T cells from 12-week-old littermate control Ceacam1flox/flox X Lck-Cre (fl/fl-Cre) or
Ceacam1flox/flox (fl/fl) mice were incubated with anti-CD3 and anti-CD28 for 48 hr and proliferation assessed by [3H]thymidine uptake in triplicate.
Data shown are representative of two experiments. Bars indicate SEM. *p < 0.05.
(G) Cytokine secretion by CEACAM1-deficient T cells. CD4+ T cells from Ceacam1flox/flox X Lck-Cre or Ceacam1flox/flox mice were incubated with
anti-CD3 and anti-CD28 for 48 hr and supernatants analyzed for IL-2 and IFN-g production by ELISA in triplicate. Data shown are representative
of two experiments. Bars indicate SEM. *p < 0.05.(Figure S2). In association with this, Ceacam1flox/flox X
Lck-Cre mice displayed enhanced proliferation (Fig-
ure 1F) and cytokine production as assessed by IL-2
and IFN-g secretion (Figure 1G) in response to anti-
CD3 and anti-CD28 stimulation in comparison to Cea-
cam1flox/flox mice. The degree of enhancement of T cell
activation observed after CEACAM1 deletion was lim-
ited relative to the inhibition observed with CEACAM1
overexpression resulting from the decreased expres-
sion of CEACAM1 in the Ceacam1flox/flox mice (see
Figure S2). Nonetheless, these studies show that CEA-
CAM1 normally functions as a coinhibitory molecule
for T cells after stimulation through the TCR.ITIM-Dependent Suppression of T Helper 1 and T
Helper 2 Cytokine Production by CEACAM1-2L
We next investigated whether the suppression of IL-2
production from CEACAM1-2L-transfected T cells was
ITIM dependent given previous observations that hu-
man CEACAM1 functions in this manner (Chen et al.,
2004). The tyrosine residues of the two ITIMs in the
Ceacam1-2L cDNA were mutated by making conser-
vative phenylalanine substitutions (Ceacam1-2L mu,
Figure S1, bottom), and then cloned into GFP-RV
(GFP-2L mu). After infection of primary CD4+ T cells
with VA, GFP-2L, or GFP-2L mu, CD4+GFP+ cells were
isolated by FACS and incubated with CD3 and CD28
Immunity
772Figure 2. ITIM-Dependent Suppression of CD4+ T Cell Growth by CEACAM1-2L
(A) After retrovirus infection, CD4+ GFP+ cells with GFP-RV vector alone (VA), GFP-2L (2L), or GFP-2Lmu (2Lmu) were cultivated in the presence of
anti-CD3 and anti-CD28 for 48 hr and proliferation assessed by [3H]thymidine uptake. Bars indicate SEM. *p < 0.01.
(B) Ex vivo Th1 and Th2 differentiation assays. Primary CD4+CD62L+CD44Lo naive T cells infected with GFP-RV (VA), GFP-2L (2L), or GFP-2L
mutant (2Lmu) were differentiated under Th1- or Th2-inducing conditions. Culture supernatants from Th1 (IFN-g) or Th2 (IL-5) conditions were
subjected to ELISA. Each condition was tested in replicates of six. Data are expressed as the mean + SEM. *p < 0.001; **p < 0.05; ***p < 0.005.antibodies. Whereas the proliferation of the CEACAM1-
2L transfectant was substantially suppressed, no sup-
pression was observed with CEACAM1-2Lmu relative
to the VA control (Figure 2A). This indicates that CEA-
CAM1-2L negatively regulates T cell activity in primary
T cells, and this function depends on the presence of
at least one of the two ITIMs.
Ligation of endogenously expressed CEACAM1 on pri-
mary mouse T cells with MHV glycoprotein leads to spe-
cific suppression of T helper 1 (Th1) but not Th2 differen-
tiation (Iijima et al., 2004). However, in transfected Jurkat
cells, overexpression of human CEACAM1-3L inhibits se-
cretion of Th1 and Th2 cytokines (Chen et al., 2004). We
therefore investigated the effects of CEACAM1 overex-
pression in primary mouse T cells. CD4+CD62L+CD44LLo
naive T cells derived from WT B6 mice were infected indi-
vidually with GFP-RV VA, GFP-2L, or GFP-2Lmu, and
CD4+CD62L+GFP+ populations were resorted and then
cultivated under Th1- or Th2-inducing conditions. Al-
though the VA-infected CD4+CD62L+ T cells were able
to be differentiated to secrete Th1 (IFN-g) and Th2 (IL-5)
cytokines after stimulation with anti-CD3, anti-CD28,
and rIL-2, such a capacity was substantially suppressed
by overexpression of CEACAM1-2L (Figure 2B). This inhi-
bition of Th1 and Th2 cytokine secretion was substan-
tially reduced, but not completely reversed, by mutation
of the two ITIM domains. These studies indicate that
CEACAM1-2L inhibits both Th1 and Th2 differentiation
of primary mouse T cells.
CEACAM1-2L Inhibits T Cell Function In Vivo in
a Pathway that Is Dependent on a Functional
cyt Tail and SHP1
To assess the in vivo significance of T cell inhibition by
CEACAM1-2L overexpression, we established a modifi-
cation of the naive T cell adoptive transfer model into
Rag22/2 recipients (Powrie et al., 1991, 1996). This mod-
ification was required because primary T cells require
prestimulation with anti-CD3 or anti-CD28 and rIL-2 to
render them permissive to retroviral infection. Stimu-
lated, but uninfected, control naive T cells transferred
into recipients induced severe colitis (Figure S3, top
left and right) based upon secretion of IL-2 and IFN-g
from mesenteric lymphocytes (ML, data not shown)
and lamina propria lymphocytes (LPL; Figure S3, bottom
left and right). The clinical severity of colitis and Th1 cy-
tokine production induced by the activated ‘‘naive’’ Tcells were inhibited by CD4+CD25+ regulatory T cells
(Treg, Figure S3), confirming the validity of this model
(Powrie, 1995; Powrie et al., 1994a; Read et al., 2000).
CEACAM1-2L-mediated suppression of T cells ex vivo
(Figure 2) was dependent upon the presence of the two
ITIMs. In addition, the L domain has been previously
shown to associate with SHP1 in mouse (Nakajima
et al., 2002) and human (Chen and Shively, 2004) T cells
ex vivo. We, therefore, next determined whether CEA-
CAM1-2L-based negative regulation occurs in vivo and
requires the ITIMs and SHP1. Ceacam1-2L or its ITIM-
mutated counterpart was retrovirally transduced into
WT or SHP1-deficient splenic naive T cells. SHP1-defi-
cient CD4+ T cells were obtained from T cell-specific
SHP1-deficient mice (L.P. and B.G.N., unpublished
data). Transfected T cells were injected into Rag22/2
mice to generate the modified naive T cell adoptive
transfer colitis model, as described above (Figure S3).
12 weeks after injection, mice were assessed for the
presence of the adoptively transferred, retrovirally
transfected T cells and clinical and pathological features
of colitis. LPLs were isolated from Rag22/2 mice, which
received naive T cells infected with GFP-RV VA or
GFP-2L and analyzed by FACS. As shown in Figure 3A,
approximately one-half of the CD4+GFP+ LPLs were
CEACAM1+ and thus derived from the naive T cells
adoptively transferred 12 weeks prior to the analysis.
Notably, mice receiving WT naive T cells transfected
with CEACAM1-2L exhibited substantially less colitis
based upon weight scores (Figure 3B), macroscopic
pathology (Figure S4), and microscopic pathology
(Figure 3C) in comparison to the mice that received T
cells infected with VA that exhibited severe colitis (Fig-
ures 3B and 3C). Absence of SHP1 in the transferred T
cells substantially reduced the inhibitory effect of CEA-
CAM1-2L as indicated by worsened severity of colitis,
but interestingly late in the course of the development
of colitis (Figures 3B and 3C). Likewise, the absence of
the ITIMs reversed the ability of CEACAM1-2L to inhibit
the severity of colitis (Figure 3B). These observations
were confirmed by a quantitative assessment of micro-
scopic pathology (Figure 3D). These studies indicate
that overexpression of CEACAM1-2L in T cells directly
inhibits the pathogenic abilities of the T cells in vivo. In
addition, this inhibitory function of CEACAM1-2L is de-
pendent upon the two functional ITIM domains and the
presence of SHP1 in the transduced T cells.
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773Figure 3. Effect of CEACAM1-L Overexpression on T Cells Is Dependent on ITIM Domains and SHP1 in Naive T Cell Adoptive Transfer Colitis
Model
(A) 12 weeks after transfer, purified LPL were stained with anti-CD4 PE or CC1 and anti-mouse IgG1 PE, followed by flow cytometry.
(B) Rag22/2mice injected with WT naive T cells that were not infected with virus (noninfected control, closed circles) or infected with GFP-RV VA
(closed squares), GFP-2L (open squares), GFP-2Lmu (open triangles), or injected with SHP1-deficient naive T cells infected with GFP-2L (SHP1-
deficient-2L, closed triangles), and noninjected control group (open circles) were monitored for wasting. Data are shown as mean 6 SEM and
represent eight mice per group.
(C) Histology (H&E stain) from colitic tissues with noninfected WT naive T cells (Stim), GFP-RV alone (VA), GFP-2L (2L), and SHP1-deficient naive
T cells with GFP-2L (SHP122L) are shown (magnification 320). One representative feature from each group of eight is shown.
(D) Quantitative histopathological assessments of colitis severity caused by WT naive T cells with VA, 2L, 2Lmu, or SHP1-deficient-2L naive T
cells are shown. Data are provided as mean + SEM and represent eight mice per group. *p < 0.01.
(E) Culture supernatants from colitic LPL were harvested for determination of IL-2 (top left), IFN-g (top right), IL-4 (bottom left), and IL-5 (bottom
right) by ELISA. Cytokines produced by LPL in colitis caused by VA, 2L, 2Lmu, and SHP1-deficient-2L naive T cells orRag22/2mice that received
stimulated wild-type CD4+CD62L+ T cells with or without Treg (Figure S3) are shown. Data are expressed as the mean 6 SEM. *p < 0.05 and
**p < 0.01.
(F) Lysates of splenic CD4+ T cells from the naive T cell adoptive transfer colitis models that received either VA, 2L, 2Lmu, or SHP1-deficient-2L
naive T cells were subjected to immunoblotting performed with either anti-phosphorylated JNK or anti-JNK.
(G) Nuclear extracts of splenic CD4+ T cells from the colitis models with either VA, 2L, 2Lmu, or SHP1-deficient-2L were subjected to western
blotting performed with either anti-STAT4, anti-STAT6, anti-T-bet, anti-GATA3, or anti-histone H1.
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and Th2 Cytokine Production in a Naive T Cell
Adoptive Transfer Colitis Model
To determine whether the suppression of colitis by over-
expression of CEACAM1-2L in T cells was associated
with alterations in production of Th1 cytokines, such
as IL-2, IFN-g (Figure 3E, top), and TNF-a (data not
shown), and for Th2 cytokines, such as IL-4 and IL-5
(Figure 3E, bottom), the amounts of cytokines produced
by SPL (data not shown), ML (data not shown), and LPL
(Figure 3E) were assessed. Activated naive T cells ex-
pressing VA that were transferred into Rag22/2 mice in-
duced high quantities of Th1 cytokine production from
SPL (data not shown), ML (data not shown), and LPL
(Figure 3E) that were similar to the amounts of Th1 cyto-
kines observed in Rag22/2mice that received nontrans-
fected, activated CD4+CD62L+ T cells (Figure S3). Ele-
vated Th2 cytokine production was also observed in
LPL derived from activated T cells infected with VA but
at substantially lower quantities than Th1 cytokine pro-
duction. Mice receiving naive T cells overexpressing
CEACAM1-2L exhibited reduced Th1 and Th2 cytokine
production by SPL (data not shown), ML (data not
shown), and LPL, together with less severe colitis. Al-
though expression of CEACAM1-2L with mutated ITIMs
(2Lmu) or WT CEACAM1-2L in SHP1-deficient T cells
(SHP122L) substantially reversed the CEACAM1-2L-
mediated inhibition of Th1 cytokine production by
LPLs, there was only limited reversal of the inhibition
of Th2 cytokine production by CEACAM1-2L. Given
that severe colitis was observed in Rag22/2 recipients
of 2Lmu and SHP1-deficient-2L T cells (Figure 3D) in
the context of suppressed Th2 cytokine production,
these studies suggest that Th1 cytokines are the major
pathologic effectors in this model, consistent with previ-
ous studies also in this adoptive transfer model (Powrie
et al., 1994b). These studies further suggest that, con-
sistent with the in vitro studies of Th1 and Th2 differen-
tiation (Figure 2B), overexpression of CEACAM1-2L can
cause suppression of Th1 and Th2 cytokine production
in vivo.
ITIM and SHP1-Dependent Suppression of Th1 and
Th2 Signal Transduction by CEACAM1-2L
Next, we examined whether CEACAM1-2L exerts a neg-
ative effect on Th1 and Th2 cytokine secretion by mod-
ulating MAPK pathways (Chen et al., 2004). Rag22/2
mice that received either WT T cells infected with the
GFP-RV VA, 2L, or 2Lmu retroviruses or SHP1-deficient
naive T cells infected with 2L (SHP122L) were examined
for mitogen-activated protein kinase (MAPK) activity in
association with colitis by subjecting splenic CD4+ T
cells from these recipient groups to immunoblotting.
As seen in Figure 3F, downregulation of phosphorylated
JNK was observed in T cells that overexpressed CEA-
CAM1-2L in comparison to the VA group. In comparison,
the inhibition of C-Jun NH2-terminal Kinase (JNK) phos-
phorylation by CEACAM1-2L was reversed by mutation
of the ITIMs or overexpression of CEACAM1-2L in an
SHP1-deficient background within T cells. The expres-
sion of phosphorylated JNK correlated with the severity
of colitis in this model (Figures 3A–3D) and cytokine pro-
duction by SPL (data not shown), MLN (data not shown),
and LPL from the colitic tissues (Figure 3E).In addition, nuclear extracts from splenic CD4+ T cells
in the mice that had received T cells infected with VA, 2L,
and 2Lmu and 2L in SHP1-deficient T cells (SHP122L)
were examined for transcription factors known to be as-
sociated with Th1 and Th2 differentiation. As can be
seen in Figure 3G, whereas substantial quantities of nu-
clear translocation of STAT4, STAT6, T-bet, and GATA-3
were observed in T cells that received the VA, these
amounts were substantially reduced in the 2L infectants
with reversal in the inhibition of STAT6, T-bet, and
GATA3, and partial reversal of STAT4 by mutation of
the ITIM (2Lmu) and expression of 2L in SHP1-deficient
T cells (SHP122L).
Generation and Characterization of CEACAM1-4L
Transgenic Mice
Given the limitations in using retroviral transduction to
examine the in vivo function of the CEACAM1-4L variant
(Figure 1), we sought an alternative experimental ap-
proach to address this issue. We created transgenic
mice in which CEACAM1-4L was expressed under the
control of the human (h) CD2 promoter (Figure S5) in or-
der to generate T cells that overexpressed CEACAM1-4L
(4L Tg). As seen in Figures 4A and 4B, WT (CD3+) T cells
express low amounts of endogenous CEACAM1 on the
cell surface (Figure 4A), with most of this likely derived
from the CEACAM1-4L splice product based upon the
apparent molecular mass of CEACAM1 as detected by
immunoblotting (Figure 4B). Introduction of the Cea-
cam1a-4L transgene increased the surface expression
of CEACAM1 on 4L Tg T cells in thymus (data not shown),
spleen (Figure 4A), and peripheral lymph nodes (data not
shown) but, interestingly, not on intestinal intraepithelial
lymphocytes (iIEL, data not shown). The latter is consis-
tent with the tight control of cell-surface CEACAM1 ex-
pression on IEL (Morales et al., 1999). Consistent with
the increased cell-surface expression of CEACAM1, 4L
Tg T cells expressed larger amounts of CEACAM1-4L
protein by immunoblotting (Figure 4B). Overexpression
of CEACAM1-4L in T cells caused a decrease in the
CD3+ T cell population in total splenocytes from the 4L
Tg mice in comparison to WT mice (Figure 4C), but not
in the thymus (Figure S5), suggesting that the effects of
CEACAM1 overexpression are mainly due to effects in
the periphery. The relative ratio of CD4+ and CD8+ T cells
in spleen and the proportion of CD4+CD25+ T cells in
lamina propria in 4L Tg mice were similar to WT mice,
suggesting that such an effect was evident among all
subsets of T cells (data not shown and Figure S5).
Because overexpression of CEACAM1-4L was ex-
pected to regulate primary T cell function, we examined
the proliferation of T cells in 4L Tg mice in comparison to
WT mice. 4L Tg T cells exhibited decreased proliferation
in comparison to WT T cells (Figure 4D) as well as de-
creased IL-2 production (Figure 4E) in response to
CD3 and CD28 antibodies. T cells from 4L Tg mice
were also less responsive than WT T cells in a MLR (Fig-
ure 4F). Moreover, 4L Tg mice exhibited decreased con-
tact hypersensitivity response to oxazolone (Figure 4G).
To further examine the function of CEACAM1-4L func-
tion to a specific nominal antigen, CEACAM1-4L Tg mice
were crossed with OT-II mice that express a transgenic
TCR specific for ovalbumin (OVA) and restricted to I-Ab
(Barnden et al., 1998). CD4+ T cells from spleen from
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(A) Total splenocytes were stained with either control IgG1 or CC1, anti-mouse IgG1 FITC, or anti-CD3 PE. Data show IgG1 (open histogram)- and
CC1 (closed histogram)-stained populations of CD3+ T cells from WT (left) and 4L Tg (right) mice.
(B) Protein lysates of CD4+ splenocytes from WT or 4L Tg mice were subjected to immunoblotting with either the CC1 mAb or a b-actin Ab.
(C) Reduction of CD3+ T cells in 4L Tg mice. Total splenocytes from WT (left) and CEACAM1-4L Tg (right) mice were stained with anti-CD3 FITC
(closed histogram). Tg panel shows overlay of CD3+ staining in WT (open histogram) and 4L Tg mice (closed histogram).
(D) Splenic CD4+ T cells isolated from B6 WT or 4L Tg mice were stimulated with anti-CD3 and anti-CD28 for 48 hr and proliferation assessed by
[3H]thymidine uptake. Data are expressed as mean 6 SEM. *p < 0.001; **p < 0.005.
(E) Splenic CD4+ T cells isolated from B6 WT or 4L Tg mice were stimulated with anti-CD3 and anti-CD28 and IL-2 production assessed by ELISA.
Bars indicate +SEM. *p < 0.001.
(F) Indicated numbers of spleen CD4+ T cells isolated from B6 WT or 4L Tg mice were subjected to MLR with mitomycin C-treated stimulator cells
derived from BALB/c mice and proliferation examined by [3H]thymidine uptake. Data are expressed as mean 6 SEM. *p < 0.005; **p < 0.001.
(G) DTH responses were measured at the indicated time points. Data are expressed in units of 0.02 mm6 SEM and represent six mice per group.
*p < 0.01, **p < 0.005.
(H) CD4+ T cells were isolated from OT-II and OT-II X 4L Tg (Tg OT-II) mice and proliferation assessed by [3H]thymidine uptake after incubation
with various concentrations of OVA protein as indicated. Data are expressed as mean 6 SEM. *p < 0.005; **p < 0.001; ***p < 0.05.
(I) CD4+ T cells were isolated from OT-II and OT-II X 4L Tg (Tg OT-II) mice and IL-2 secretion assessed by ELISA after incubation with 300 mg/ml
OVA protein. Bars indicate +SEM. *p < 0.005.OT-II and CEACAM1-4L Tg X OT-II mice were examined
for their response to OVA (Figures 4H and 4I) and
OVA323-339 (data not shown), the peptide of OVA to which
OT-II T cells are specific, when presented by SPL as an-
tigen-presenting cells from C57BL/6 mice. CD4+ T cells
from CEACAM1-4L Tg X OT-II mice exhibited decreased
proliferation (Figure 4H) and IL-2 production (Figure 4I) in
response to OVA and OVA peptide (data not shown) in
comparison to OT-II mice. These studies show that
CEACAM1-4L regulates the response of T cells to a spe-
cific nominal antigen when presented by MHC class II.
The functionality of 4L Tg T cells allowed for the op-
portunity to assess the role of CEACAM1-4L in primary
T cells in the conventional naive T cell adoptive transfercolitis model. Splenic CD4+CD62L+CD44Lo naive T cells
were isolated from WT or 4L Tg mice and injected into
Rag22/2 mice. Rag22/2 mice that received 4L Tg naive
T cells exhibited less severe wasting, compared to the
recipients of WT T cells (Figure 5A). This was associated
with less severe macroscopic (Figure S5) and micro-
scopic (Figures 5B and 5C) colitis. Moreover, lessened
pathological injury was associated with decreased Th1
(IFN-g and IL-2) cytokine production by colonic LPL
(Figure 5D). Taken together, these studies with the 4L
Tg mice indicate that overexpression of CEACAM1-4L
in primary T cells inhibits TCR-CD3 complex-stimulated
T cell functions and the ability of these cells to secrete
cytokines and cause inflammation in vivo.
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776Figure 5. CEACAM1-4L Tg Naive T Cells Suppresses Conventional Transfer Colitis
(A)Rag22/2mice injected with WT or Tg naive T cells were monitored for wasting. Data are expressed as mean6 SEM and represent 12 mice per
group. Mice that did not receive T cells are shown in open circles, adoptively transferred WT cells in closed circles, and Tg T cells in open
squares.
(B) H&E-stained histological features from colitic tissue with WT (top and bottom left) and Tg naive (bottom right) T cells are shown. Black arrow
indicates ulcer and black arrowhead indicates mononuclear cell infiltration. White arrows indicate epithelial hyperplasia in top left panel and
crypt abscesses or polymorphonuclear infiltration in the top right and bottom left panels.
(C) Quantitative histopathological assessments of colitis severity by WT or Tg naive T cells are shown. Data are provided as mean + SEM.
*p < 0.01.
(D) Th1 cytokine (IFN-g and IL-2) production from LPL in colitis tissues caused by WT or Tg naive T cells is shown. Data are expressed as mean +
SEM. **p < 0.05.Discussion
Understanding the regulation of T cell activation is cen-
tral to unraveling the mechanisms underlying autoimmu-
nity and inflammation. We here show that the two known
isoforms of mouse CEACAM1 that contain a long cyt tail
domain with ITIMs, CEACAM1-2L and -4L, are able to in-
hibit a broad array of T cell activities as a consequence
of TCR ligation, including proliferation and alloactivation
and Th1 and Th2 cytokine production associated with
tissue injury. These properties of CEACAM1 were shown
to depend on the presence of the ITIMs and SHP1. Be-
cause CEACAM1-L isoforms are normally expressed to
a greater extent than the isoforms containing a short
cyt tail domain lacking ITIMs, our studies indicate that
CEACAM1 is an inhibitory coreceptor in T cells. This is
consistent with prior in vitro functional studies of CEA-
CAM1 in T cells that demonstrate an ability of CEACAM1
to co-cap with CD3 (Chen and Shively, 2004).
In the current report, we observed that overexpres-
sion of CEACAM1-2L on naive T cells led to inhibition
of in vitro T cell differentiation to both Th1 and Th2 cells
and to in vivo inhibition of Th1 and Th2 cytokine secre-
tion by lamina propria T cells in an adoptive transfer co-
litis model. Consistent with this, overexpression of CEA-
CAM1-2L also inhibited nuclear translocation of T-bet,GATA-3, STAT-4, and STAT-6 in adoptively transferred
splenic T cells. The inhibition of STAT-4 and STAT-6
suggests that CEACAM1 inhibits not only TCR-CD3 sig-
naling in T cells but also likely IL-4 and IL-12 receptor
signaling. The latter is consistent with previous studies
showing CEACAM1 inhibition of IL-2R signaling (Chen
and Shively, 2004). Moreover, this inhibition of Th1 cyto-
kines by CEACAM1 was dependent on the ability of
CEACAM1 to elicit an inhibitory signal through the ITIMs
and SHP1 in the T cell, because individual deletion of ei-
ther factor abrogated the inhibitory effect of CEACAM1-
2L. These studies suggest that CEACAM1 is capable of
inhibiting both pathways of cytokine secretion when the
quantities of cell-surface CEACAM1 expression achieve
a critical amount. This is consistent with studies with hu-
man CEACAM1-3L, which, when overexpressed in Ju-
rkat cells, was similarly able to inhibit both Th1 and
Th2 cytokine secretion in an ITIM-dependent pathway
(Chen et al., 2004). These studies also suggest that
Th1 pathways may be more sensitive to CEACAM1-me-
diated suppression than Th2 pathways, a result that is
similar to previous observations with PD-1 and PD-1 li-
gand interactions (Latchman et al., 2001). In addition,
deletion of the ITIMs or SHP-1 only partially abrogated
the inhibitory functions of CEACAM1 on Th2 differentia-
tion and cytokine secretion in vitro and in vivo and
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hibition. Whether this represents differing sensitivities of
Th1 and Th2 cytokine pathways to TCR signal strength
when modulated by CEACAM1 (Takato-Kaji et al.,
2005) or mechanisms by which CEACAM1-L regulates
Th2 cytokines independently of ITIMs and SHP-1 (such
as regulation of IL-2 per se, which plays an important
role in Th2 differentiation) (Yamane et al., 2005) remains
to be defined.
CEACAM1-2L also suppressed the proliferation of pri-
mary T cells in vitro in a pathway that was also depen-
dent upon the presence of the two ITIMs. Consistent
with this, JNK activation was inhibited in vivo after adop-
tive transfer of naive T cells overexpressing CEACAM1-
2L. These results are consistent with and extend our
previous observation and the observation of others
that the human CEACAM1-3L and CEACAM1-4L iso-
forms inhibited the activation of the NFAT-AP-1 ele-
ments of the IL-2 promoter and IL-2 receptor expres-
sion, respectively, in Jurkat transfectants in a pathway
that involves SHP1 regulation of MAPK activity (Chen
and Shively, 2004; Chen et al., 2004). These studies
also indicate the ability of CEACAM1-2L to inhibit multi-
ple different T cell functions that are downstream of
the TCR-CD3 complex, suggesting a proximal effect
of CEACAM1 in TCR-CD3 complex signaling events.
In this study, we have also shown that overexpression
of CEACAM1-2L by retroviral transfection and CEA-
CAM1-4L by generation of a T cell-specific transgenic
animal model inhibits the ability of primary naive T cells
to induce colitis. This indicates that regulation of T cells
in vivo is imposed not only by cytokines from regulatory
populations but also by the expression of inhibitory
coreceptors on the T cell. In our studies with the CEA-
CAM1-2L, the original model as described by Powrie
and colleagues (Powrie et al., 1994b) was modified
slightly in that the adoptively transferred T cells required
activation. It should be noted that the in vitro activation
as used here did not alter the cell-surface expression of
CD62L (data not shown). In addition, the ability of the
stimulated naive T cells to cause colitis could be simi-
larly suppressed by the cotransfer of CD4+CD25+ Treg.
This inhibitory property of CEACAM1-2L was not related
to an alteration induced by activation because similar
transfer of CD4+CD62L+CD44Lo naive T cells from the
4L Tg mice was also able to suppress colitis without
prior ex vivo activation.
Importantly, inhibition of the ability of naive T cells to
cause colitis by CEACAM1 overexpression occurred in
the absence of cotransferred Treg. Analysis of lamina
propria mononuclear cells showed suppressed produc-
tion of IL-10 (data not shown) as well as the other Th2
cytokines, but no substantial alteration in TGF-bproduc-
tion (data not shown). This suggests that CEACAM1-
mediated inhibition occurs independently of these
inhibitory cytokines. It is thus predicted that CEACAM1-
driven regulation of pathogenic T cells differs from that
imposed by regulatory cytokines from Treg and may
involve either homotypic T-T interactions between CEA-
CAM1 on opposing T cells or heterotypic interactions
between the CEACAM1 expressed on effector T cells
with a variety of sources of potential CEACAM1 ligands,
including those expressed by dendritic cells, mono-
cytes, and intestinal epithelial cells. Such a model ofT-T interaction for regulation of effector T cells has
been suggested by others (Fuss et al., 2002; Powrie
et al., 1994a).
Retroviral overexpression of CEACAM1-4L also in-
hibited the proliferative capability of the expanded T
cells and their ability to secrete IL-2 to a larger extent
than the CEACAM1-2L isoform. Consistent with this,
CEACAM1-4L retroviral infectants propagated less well
than did CEACAM1-2L infectants. This suggests that
CEACAM1 with more extracellular Ig domains may be
a more potent regulator of T cells. This notion is sup-
ported by homophilic adhesion between a four than
a two Ig domain-containing isoform of CEACAM1
(Watt et al., 2001). However, the potent inhibition of T
cell function by the CEACAM1-4L isoform limited in
vivo manipulation of retrovirally transfected T cells. To
circumvent this limitation, a transgenic mouse was gen-
erated to assess the biologic function of CEACAM1-4L.
As predicted, the overexpression of CEACAM1-4L was
observed in T cells from thymus (data not shown),
spleen (Figure 4), mesenteric lymph node, and lamina
propria (data not shown). Given that the 4L Tg mice ex-
hibited decreased numbers of CD3+ cells, it is possible
that overexpression of CEACAM1-4L encoded by the
hCD2 promoter-driven transgene leads to suppression
of T cell development in the thymus, antigen-driven
expansion, and/or increased sensitivity to activation-
induced cell death. However, we observed no overt
abnormalities in the proportion of CD3-positive cells
within the thymus. Given the diminished responsiveness
of the 4L Tg T cells to an allo-MLR and the inability to
cause colitis and generate contact hypersensitivity, as
shown here, such effects of CEACAM1 on T cells are
likely to be important for regulating the T cell functions
that lead to their aggressive behavior. In a corollary fash-
ion, conditional deletion of CEACAM1 signaling function
in T cells led to T cell hyperactivity. These studies with 4L
Tg mice and mice in which CEACAM1 is conditionally
deleted in T cells provide a direct demonstration that
CEACAM1 on T cells is a coinhibitory receptor for
TCR-CD3 complex signaling.
In summary, we have shown that CEACAM1 isoforms
expressing a long cyt tail have the general property of
negatively regulating T cell responses that are initiated
by antigen-MHC complex-mediated signals. Moreover,
we have demonstrated that this is clinically relevant, be-
cause CEACAM1 functions in the suppression of colitis
in an adoptive transfer model. Defining the mechanisms
of CEACAM1-mediated T cell regulation may provide in-
sights into therapeutic methods for the treatment of IBD
and other immune-mediated disorders.
Experimental Procedures
Constructs for Retrovirus Transfection
EcoRV and XhoI restriction sites were introduced at the 50 and 30
ends, respectively, of each of the Ceacam1a-4L or -2L cDNAs, which
were cloned into the pBluescript (pBS)-SK(+) and kindly provided by
N. Beauchemin (McGill University, Montreal, Quebec, Canada), by
PCR utilizing the following primers: 50-CCTGATATCGAGACATGGA
GCTGGCCT-30 and 50-CCGCTCGAGCTCACTTCTTTTTTACTTCTG-30.
The retrovirus vector GFP-RV (Neurath et al., 2002; Ouyang et al.,
1998, 2000; Szabo et al., 2000), kindly provided by K. Murphy
(Washington University School of Medicine, St. Louis, MO), was
digested with BglII, modified with Klenow fragment to create blunt
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-2L fragments were then cloned into the digested GFP-RV, resulting
in GFP-4L or -2L, respectively.
Generation of ITIM Mutations of CEACAM1-2L
The pBS-Ceacam1-2L Y308F mutant containing a phenylalanine
substitution at aa308 was generated by PCR-directed mutagenesis
of the pBS-Ceacam1-2L with the following primers: 50-GTGGAT
GACGTCGCATTCACTGTCCTGAAC-30 (forward primer) and 50-
GAAGTTCAGGACAGTGAATGCGACGTCATC-30 (reverse primer)
with Platinum Pfx polymerase (GIBCO Invitrogen). The vector en-
coding Ceacam1-2L Y308F Y335F (pBS-Ceacam1-2L mu) contain-
ing two phenylalanine substitutions was generated by PCR of the
pBS-Ceacam1-2L Y308F with the following primers: 50-GCCACA
GAAACAGTTTTTTCAGAAGTAAAAAAG-30 (forward primer) and 50-
CTTCTTTTTTACTTCTGAAAAAACTGTTTCTGTG-30 (reverse primer).
PCR products were digested with DpnI to remove prokaryotic tem-
plate DNA. The Ceacam1-2L mu cDNA was cloned into the GFP-RV
vector as described above.
Cell Lines, Cell Culture, and Retrovirus Transfection
The ecotrophic packaging cell line, Phoenix-E (Hofmann et al.,
1996), derived from human embryonic kidney line 293 was kindly
provided by G. Nolan (Stanford University, Stanford, CA). NIH3T3
cells were purchased from American Type Culture Collection (Man-
assas, VA). High-titer retrovirus supernatants were prepared by lip-
ofection (Effectene, Qiagen, Valencia, CA) of Phoenix-E cells with
the GFP-RV constructs for the retrovirus transfection as previously
described (Neurath et al., 2002; Szabo et al., 2000). Subsequently,
cells were analyzed by FACS and GFP+ cells sorted.
Animals
Wild-type (WT) C57BL/6 (B6) or RAG2-deficient (Rag22/2, B6) mice
were purchased from Charles River Breeding Laboratories (Wil-
mington, MA) or Taconic Farms Inc. (Germantown, NY), respectively.
T cell-specific SHP1-deficient mice were generated by crossing
mice with ‘‘floxed’’ alleles of SHP1 (L.P., K.P. Lam, M.L. Thomas,
and K. Rajewsky, unpublished data) with transgenic mice express-
ing the Cre DNA recombinase under the control of CD4 promoter
(Lee et al., 2001). All mice used were in mixed B6/129 background.
Mice were maintained under specific pathogen-free conditions at
the Animal Facilities of Harvard Medical School. All animal experi-
mentations were performed in accordance with institutional guide-
lines and the Animal Review Board of Harvard Medical School which
granted permission for this study.
Antibodies and Reagents
A monoclonal antibody (mAb) specific for mouse CEACAM1, CC1,
was previously established by K.V. Holmes (University of Colorado
Health Sciences Center, Denver, CO) (Dveksler et al., 1993). CD4 Cy-
Chrome, CD4 PE, L-selectin (CD62L) PE, CD44 FITC, and CD25 PE
Abs were purchased from BD Biosciences (San Jose, CA). JNK,
phosphorylated JNK, STAT4, STAT6, T-bet, GATA3, and histone H1
Abs were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Human rIL-2 for the stimulation of mouse primary T cells was
purchased from Roche Diagnostics Corporation (Indianapolis, IN).
Immunoblotting and Flow Cytometry
The expression of CEACAM1, JNK, p-JNK, T-bet, GATA-3, STAT4,
and STAT6 were assessed by immunoblotting by standard proto-
cols as previously described (Chen et al., 2004). Flow cytometry
(FACS) was performed with a FACSort (BD Bioscienses) after
GFP-RV infection and/or staining by standard methods as previ-
ously described (Nakajima et al., 2002).
Preparation of CD4+ T Cells and Proliferation Assays
Splenic CD4+ T cells were isolated from mice by magnetic immuno-
beads (MACS, Miltenyi Biotech, Germany) according to the manu-
facturer’s instructions, and retroviral infection was performed. For
proliferation assays, 23 105 sorted GFP+CD4+ T cell were incubated
for 48 hr in 96-well flat bottom microtiter plates at 37C in 5% CO2 in
the presence of 5 mg/ml plate-bound anti-CD3 and 2 mg/ml soluble
anti-CD28. Proliferation assays were performed by addition of
[3H]thymidine (1.0 mCi/well) for 18 hr.Preparation of Naive T Cells and In Vitro Th1 and Th2
Differentiation Assays
Whole splenic mononuclear cells derived from either WT or SHP1fl/fl
CD4-Cre mice were subjected to B cell depletion by negative selec-
tion with CD19 MACS beads (Miltenyi Biotech). Subsequently,
CD4+CD62L+CD44Lo naive T cells were sorted by BD FACSAria or
a negative selection column (R&D Systems, Minneapolis, MN) as
previously described (Neurath et al., 2002), and the isolated naive
T cells were used for retroviral infection. After prestimulation with
anti-CD3-anti-CD28 and rIL-2, followed by retroviral infection, the
GFP+CD4+CD62L+ population was resorted. 5 3 105 sorted cells
were incubated in 100 ml complete RPMI-1640 with 1 mg/ml plate-
bound anti-CD3 and 1 mg/ml soluble anti-CD28 and, for Th1 cells,
supplemented with 5 ng/ml rIL-12 (R&D Systems) and 5 mg/ml IL-4
Ab (BD Biosciences) at 37C in 5% CO2 for 72 hr. For the generation
of Th2 cells, 50 ng/ml rIL-4 (R&D Systems), 1 mg/ml anti-IL-12, and 10
mg/ml anti-IFN-g (BD Biosciences) were used to supplement the cul-
ture medium. Cells were washed twice with PBS and restimulated in
complete RPMI-1640 with the same concentrations of CD3 and
CD28 Abs for 48 hr. Culture supernatants were harvested for cyto-
kine ELISA (Opt EIA set, BD Biosciences) according to the manufac-
turer’s instructions.
Generation of CEACAM1-4L Transgenic Mice
EcoRI restriction sites were introduced at the both the 50 and 30 ends
of the Ceacam1-4L cDNA by PCR via the following primers: 50-
CCGGAATTCGAGACATGGAGCTGGCCT-30 and 50-CCGGAATTCT
CACTTCTTTTTTACTTCTG-30. The VACD2 cassette (Zhumabekov
et al., 1995), which was cloned into pBS-SK(-), was kindly provided
by M. Owen (Imperial Cancer Research Fund, London, UK). pBS-
VACD2 DNA was digested with EcoRI followed by 50 end dephos-
phorylation with calf intestinal alkaline phosphatase (NEB) to pre-
vent self-ligation. The EcoRI-digested Ceacam1-4L fragment was
then cloned into the digested pBS-VACD2 and double digested
with KpnI and XbaI to remove prokaryotic plasmid sequences, re-
sulting in VACD2-Ceacam1-4L. The microinjection of the transgene
construct into 0.5 day B6 embryos was performed at the Transgenic
Core Facility of the Brigham and Women’s Hospital, Harvard Medi-
cal School. Genotyping for Tg mice was performed by PCR of geno-
mic DNA purified from tail tissues with specific primer pairs: 50-
TCAATGGTGACTTCAGCAGTGGTG-30 and 50-CGTGGTTAAGCTCT
CGGGGTG-30 specific for the region between hCD2 promoter to
the extracellular domain of Ceacam1, and 50-GGAAGTACGGATATG
CACATCAGG-30 and 50-ATAGCAGGGCTGGCATATTTCC-30 specific
for the region between L domain of Ceacam1 to hCD2 LCR.
Generation of OT-II X CEACAM1-4L Tg Mice
OT-II mice (kindly provided by J. Ravetch, Rockefeller University,
New York, NY) were crossed with CEACAM1-4L Tg mice. CD4+ T
cells from spleen from OT-II X CEACAM1-4L Tg mice were incubated
with OVA or OVA peptide (323–339) at the indicated concentrations
with splenocytes from B6 mice as antigen-presenting cells. IL-2 in
the supernatant was measured after 24 hr and proliferation as-
sessed after 48 hr by means of [3H]thymidine uptake.
Generation of CEACAM1-Deficient Mice
A conditional knockout construct was designed to delete exons 7–9
encoding the cyt tail of CEACAM1. The targeting construct was de-
signed by inserting a loxP-neo cassette at the XmnI site in intron 6
and a loxP fragment at the HindIII site in intron 9 of Ceacam1 in
a BAC clone from a 129Sv library (Figure S2, top). The targeting vec-
tor included 4.3 kb of homologous DNA upstream of the loxP-neo
site and 3.4 kb of homologous DNA downstream of the second
loxP site. The targeting vector was verified by restriction mapping.
The targeting vector was transfected into 129Sv embryonic stem
(ES) cells by electroporation. Clones that contained a hybridization
signal at the size (8.1 kb), predicting for the homologous recombi-
nant allele after SphI digestion with a 0.7 kb Apa1 and SpeI fragment
of Ceacam1 as a probe, were identified from 270 ES cell candidates.
The genomic DNAs of these potential positive clones were digested
with XhoI and hybridized with a 30 probe (a 1.2 kb SacI and XhoI frag-
ment of Ceacam1) and clones that exhibited aw17.1 kb band corre-
sponding to the recombinant allele were identified. Three positive
ES cell clones were injected into mouse blastocysts according to
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B6 mice. The F1 mice having germline transmission of the loxP-tar-
geted Ceacam1 allele were interbred to generate F2 mice. Germline
transmission was confirmed by PCR of tail DNA tissue with the
following three primers that detect the WT and the floxed allele of
Ceacam1 (and the Ceacam2) gene (Han et al., 2001): primer A (50-
ACACAAGGAGGCCTCTCAGATGGCG-30) and primer C (50-GCGCC
TCCCCTACCCGGTAGAATT-30), containing sequences from exon
6 of Ceacam1 and neomycin cassette, respectively, produce a 488
bp PCR product from the floxedCeacam1 allele. Primer A and primer
B (50-GACTTTGGCTTCCTGACTGGAGGA-30), containing sequences
from intron 6, generate a 382 bp PCR product from WT Ceacam1.
Two founder mice from two embryonic cell clones showed germline
transmission of the targeting construct containing the conditional
Ceacam1 gene (Figure S2, middle left). Mice with homozygous con-
ditional Ceacam1 alleles were born from these two founder mice.
These results indicate that embryonic lethality does not occur in
the mice carrying conditional Ceacam1 knockout alleles.
Ceacam1flox/flox homozygous mice were examined for their ex-
pression of CEACAM1 protein by immunoblotting liver cell lysates
with Ab669, an Ab recognizing the entire CEACAM1. Decreased
CEACAM1 expression was observed in liver (Figure S2, middle cen-
ter) and on the cell surface of B cells (Figure S2, bottom left) of Cea-
cam1flox/flox mice in comparison to WT littermates typical of many
neo containing recombinantly inserted genes. The functionality of
the floxed cassette was tested with recombinant adenovirus with
the Cre gene (Ad-Cre). Ceacam1flox/flox mice were treated with Ad-
Cre or control virus Ad-Luc (containing the firefly luciferase gene)
by i.v. injection. Immunoblots were performed on liver lysates at
21 days after injection. As shown in Figure S2 (middle right), there
was a substantial decrease in the amount of L cyt tail containing iso-
forms of CEACAM1 in the mouse treated with Ad-Cre. This observa-
tion shows that exons 7–9 of CEACAM1 can be removed by treat-
ment of Ceacam1flox/flox mice with Cre recombinase. As a result,
Ceacam1flox/flox mice were crossed with lck-Cre mice (Taconic Lab-
oratories, C57BL/6Ntac-TgN) that express Cre under the control of
the proximal Lck promoter to generate Ceacam1flox/flox X lck-Cre
mice allowing for deletion of CEACAM1 signaling function specifi-
cally in T lymphocytes.
Mixed Leukocyte Reaction
Splenocytes (5 3 104) derived from WT BALB/c mice were treated
with 100 mg/ml mitomycin C (Sigma-Aldrich, St. Louis, MO) and
used in an allogeneic MLR with 5 3 104 WT (B6) or CEACAM1-4L
Tg (B6) CD4+ T cells as previously described (Nakajima et al., 2002).
Delayed-Type Hypersensitivity
Mice were presensitized by painting 150 ml of 3% 4-ethoxymethy-
lene-2-phenyl-2-oxazolin-5-one (oxazolone, Sigma-Aldrich) dis-
solved in 1:3 acetone-ethanol mixture onto the shaved abdomen.
4 days after the presensitization, local skin challenge via topical ap-
plication to both sides of the ears with 1% oxazolone in 20 ml of 1:1
acetone-sunflower oil mixture was performed (Szczepanik et al.,
1996). Ear swelling was measured with a dual thickness gauge (Mit-
sutoyo Mfg. Co., Tokyo, Japan).
Colitis Models
CD4+CD62L+CD44Lo naive T cells were isolated from WT or
SHP1flox/flox CD4-Cre mice, and the isolated naive T cells were in-
fected with retroviruses. After staining with anti-CD4 CyChrome
and CD62L PE Abs, GFP+CD4+CD62L+ cells were resorted. Purified
43 105 cells (purity; >97%) were injected intraperitoneally into 8- to
10-week-old female Rag22/2 mice. In some experiments,
CD4+CD25+ regulatory T cells (Treg) were sorted with CD4 Cy-
Chrome and CD25 PE Abs, then cotransferred with naive T cells. Af-
ter the injection, wasting was monitored for 12 weeks.
Histological Assessment of Colitis
Colonic tissues were fixed in 10% buffered formalin phosphate and
embedded in paraffin, cut into sections, and then stained with hema-
toxylin and eosin and evaluated by a pathologist, J. Glickman (Brig-
ham and Women’s Hospital, Harvard Medical School), who was
blinded to the treatment of the mice. Evidence and severity of colitiswere defined by means of a scoring system as previously described
(Brozovic et al., 2004; Iijima et al., 2004; Neurath et al., 2002).
Lymphocyte Isolation and Determination of Cytokine
Production
Single-cell isolations from spleen and mesenteric lymph nodes were
performed with a 40 mm cell strainer (BD) and ACK solution for deple-
tion of red blood cells. Colonic lamina propria lymphocytes (LPL)
were isolated as previously described (Iijima et al., 2004; Neurath
et al., 2002).
Isolated splenocytes (SPL), mesenteric lymphocytes (ML), or LPL
(5 3 105 each) were cultured in complete RPMI-1640 supplemented
with 50 mM b-mercaptoethanol (Sigma-Aldrich) and 10 mg/ml genta-
mycin (BioWhittaker) for LPL, and 5 mg/ml plate-bound anti-CD3 and
2 mg/ml soluble anti-CD28 in flat bottom 96-well plate at 37C in 5%
CO2 for 48 hr. Culture supernatants were harvested and cytokine
production determined (IL-2, IFN-g, TNF-a, IL-4, IL-5, IL-10, and
TGF-b) by ELISA (BD Biosciences) according to the manufacturer’s
instructions.
Statistical Analysis
Data were expressed as the mean6SEM and statistical significance
determined by the Student’s t test. For some experiments, statistical
analyses were conducted by means of the analysis of variance fol-
lowed by an evaluation of pairwise differences among the means
with Bonferroni tests. p values <0.05 were considered significant.
Supplemental Data
Five Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/5/769/DC1/.
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